Back to top
more

Nyxoah (NYXH)

(Delayed Data from NSDQ)

$9.44 USD

9.44
24,518

-0.11 (-1.15%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $9.63 +0.19 (2.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Privia Health (PRVA) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of -2.22% and 56.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 125% and 5.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 46.03% and 1.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of 0% and 2.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Nextgen Healthcare (NXGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 24% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NYXH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of -8.89% and 15.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of -32.43% and 61.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 21.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of 100% and 2.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?

by Zacks Equity Research

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Nyxoah SA (NYXH) Could Rally 170%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 170.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CareCloud, Inc. (MTBC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareCloud, Inc. (MTBC) delivered earnings and revenue surprises of 46.15% and 0.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?

by Zacks Equity Research

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Computer Programs and Systems (CPSI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 22.73% and 3.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Nyxoah (NYXH) Ahead of Earnings?

by Zacks Equity Research

Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Nyxoah (NYXH) Ahead of Earnings?

by Zacks Equity Research

Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.